Skip to main content
SpringerLink
Log in

Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Gastrointestinal symptoms are fairly common in diabetes mellitus. Glimepride, is a latest second generation sulfonylurea used for the treatment of type II diabetes mellitus, is a insulin secrectagogue; indirectly, it also increases insulin secretion and its specific effect on pancreatic ATP-dependent K+ channel inhibition. Esomeprazole, the (S)-isomer of omeprazole, is the first proton pump inhibitors developed as a single isomer for the treatment of acid-peptic diseases by specific inhibition of H+/K+-ATPase in gastric parietal cell. Since there is possibility for drug interaction leading to decreased activity of glimepride, the present study was conducted to evaluate the effect of the combination. Studies in normal and alloxan induced diabetic rats were conducted with oral doses of 135 μg/kg bd.wt. of glimepride, 3.6 mg/kg bd.wt. of esomeprazole, and their combination with adequate washout periods in between treatments. Studies in normal rabbits were conducted with doses 70 μg/1.5 kg bd. wt. of glimepride, 1.8 mg/1.5 kg bd. wt. of esomeprazole, and their combination given orally. The blood samples were collected at 0, 1, 2, 4, 8, 12, 18, 24 h and analyzed for glucose levels by GOD/POD method and insulin in diabetic rats by radioimmunoassay methods. Glimepride produced hypoglycaemic/antidiabetic activity in normal and diabetic rats activity with peak activity maximum at 4 h and hypoglycemic activity in normal rabbits maximum at 4 h and esomeprazole increases the insulin levels in diabetic rats. The study also suggests the necessity to readjust the dose of glimepride, when used concomitantly with esomeprazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ramesh KG, Parloop AB, Mahesh DB (2004) Elements of clinical pharmacy, 1st edn. BS Shah Prakashan, Ahmedabad, pp 135–148

    Google Scholar 

  2. Kubacka KJ, Antal AL, Juhl RP (1987) Paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetic and pharmacodnamics. Br J Clin Pharmacol 23:743–751

    CAS  PubMed  Google Scholar 

  3. Rajendra SV, Raghaveergupta PS, Joshi VG, Anand Kumar Y, Venkantrao N, Ramchandra Setty S (2004) Influence of lansoprazole on hypoglycemic activity of oral antidiabetic agent in healthy albino rats. Acta Pharm Turc 46:95–99

    CAS  Google Scholar 

  4. Prichard PJ, Wait RP, Kitchingman GK, Somerville KW, Langman MJ, Williams J et al (1987) Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24:543–545

    CAS  PubMed  Google Scholar 

  5. Kumar V, Venakat Rao N, Ramachandra Setty S (2000) Influence of omeprazole on hypoglycemic activity of glibenclamide and tolbutamide normal albino rabbits. Acta Pharm Turc 42:135–138

    CAS  Google Scholar 

  6. Hassan-Alin M, Adersoon T, Bredberg E, Rohss K (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56:665–670

    Article  CAS  PubMed  Google Scholar 

  7. Drager E (1995) Clinical profile of glimepride. Diabet Res Clin Pract 28(Suppl:S):138–139

    Google Scholar 

  8. Song DK, Ashcroft FM (2001) Glimepride block cloned β-cell, cardic and smooth muscle K+ATP channels. Br J Pharmacol 133(1):193–199

    Article  CAS  PubMed  Google Scholar 

  9. Klepzig H, Kobert G, Matter C, Luss H, Schneider H et al (1999) Sulfonylureas and ischemic preconditioning, A double-blind, placebo-controlled evaluation of glimepride and glibenclamide. Eur Heart J 20(6):439–446

    Article  CAS  PubMed  Google Scholar 

  10. Sane RT, Mnon SN, Shafi Inamdar et al (2004) Simultaneous determination of pioglitazone and glimepride by high-performance liquid chromatography. Chromatographia 59:451–453

    Article  CAS  Google Scholar 

  11. Esplugues JV, Marthi-Cabrera M, Ponce J (2006) Safety of proton pump inhibitors. Med Clin (Barc) 127:790–795

    Article  Google Scholar 

  12. Larsson H, Carlsson E, Junggren U, Olbe L, Sjostrand SE, Skanberg I, Sundell G (1983) Inhibition of gastric acid secretion by omeprazole in dog and rat. Gastroenterology 85(4):900–907

    CAS  PubMed  Google Scholar 

  13. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura H (1989) Antisecretory and antiulcer activites of a novel proton pump inhibitors AG-1749 in dogs and rats. J Pharmacol Exp Ther 248:806–815

    CAS  PubMed  Google Scholar 

  14. Bastaki SalimMA, Chandranath IrwinS, Singh Jaipaul (2008) The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Mol Cell Biochem 309:167–175

    Article  CAS  PubMed  Google Scholar 

  15. Lawrence DR, Bacharach AL (1964) Evaluation of drug activities. In: Pharmacometrics, vol I. Academic Press, New York, USA

  16. Riley V (1960) Adaption of orbital bleeding technique to rapid serial blood studies. Proc Soc Exp Bio Med 104:751–754

    CAS  Google Scholar 

  17. Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non carcinogenic chemogen. J Clin Pathol 22:158–161

    Article  CAS  PubMed  Google Scholar 

  18. Manonmani G, Bhavapriya V, Kalpana S, Govindasamy S, Apparanantham T (2005) Antioxidant activity of Cassia fistula (Linn.) flowers in alloxan induced diabetic rats. J Ethno Pharmacol 97(1):39–42

    CAS  Google Scholar 

  19. Venkatesh S, Reddy DG, Reddy BM, Ramesh M, Rao AV (2003) Antihyperglycemic activity of Caralluma attenuate. Fitoterpia 74:274–279

    Article  CAS  Google Scholar 

  20. Satyanarayana S, Nitin M, Prasad K (2007) Pharmacodynamic and pharmacokinetic drug interaction of disopyramide with tolubutamide in rabbits. Indian drugs 44(9):683–688

    Google Scholar 

  21. Giuseppe D, Arrigo FG, Cicerob AntonioG, Pietro RD et al (2005) A comparison of the effect of pioglitazone and rosiglitazone combined with glimepride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 69(1):5–13

    Article  Google Scholar 

  22. Olbrich HG, Muller M, Lindner S, Henke B, Zarse M, Riehle M, Oremek G, Mutschler E (1999) Glimepride inhibits the rilmakalim induced decrease in intracellular free calcium and contraction of isolated heart muscle cells from guinea pigs to a lesser extent than glibenclamide. Int J Cardiol 72:53–63

    Article  CAS  PubMed  Google Scholar 

  23. Satyanarayana S, Kilari EK (2006) Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem 291:101–105

    Article  CAS  PubMed  Google Scholar 

  24. Gribble FM, Reimann F (2003) Differential selectivity of insulin secrectagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat 17(2):11–15

    Article  PubMed  Google Scholar 

  25. Rajan AS, Aguilar-Bryan L, Nelson DA, Yaney GC, Hsu WH, Kunze DL, Boyd AE (1990) Ion channels and insulin secretion. Diabetes Care 13(3):340–363

    Article  CAS  PubMed  Google Scholar 

  26. Klotz U (2000) Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 38(3):243–270

    Article  CAS  PubMed  Google Scholar 

  27. Campbell RK (1998) Glimepride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmcother 32(10):1044–1052

    Article  CAS  Google Scholar 

  28. Gunter M, Detlev H, Jurgen P, Raymond O, Werner K (1994) Differential interaction of glimepride and glibenclamide with the β-cell sulphonylurease receptor I. Binding characteristics. Biochem et Biophysica Acta 1191:267–277

    Article  Google Scholar 

  29. Langtry HD, Balfour JA (1998) Glimepride, a review of its use in the management of type 2 diabetes mellitus. Drugs 55:563–584

    Google Scholar 

Download references

Acknowledgments

The authors are thankful to Aurochem Pharmaceutical, Palghar and Alcon Bioscence, Vapi for supplying gift samples of glimepride and esomeprazole, respectively.

Author information

Authors and Affiliations

  1. Post Graduate Department of Pharmacology and Research Centre, H. S. K. College of Pharmacy, Bagalkot, Karnataka, 587101, India

    Prashant D. Phadatare & V. M. Chandrashekhar

Authors
  1. Prashant D. Phadatare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. M. Chandrashekhar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prashant D. Phadatare.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phadatare, P.D., Chandrashekhar, V.M. Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem 354, 135–140 (2011). https://doi.org/10.1007/s11010-011-0812-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-011-0812-7

Keywords

Search

Navigation